Last December, the company raised its quarterly payout for the 16th consecutive year. The dividend yield investors could ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Pfizer (NYSE:PFE) develops and sells biopharmaceutical products, including vaccines, treatments for infectious diseases, ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

Woes for U.S. healthcare stocks have worsened this year driven partly by Trump administration policies, although some ...

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Metro Bank Holdings PLC (NYSE: MCB) (LSE:MTRO) results are flagged by market analyst Victoria Scholar at Interactive Investor ...

AST SpaceMobile Inc. (NASDAQ:ASTS) is broadening its satellite spectrum portfolio through a new agreement to obtain global ...